JP2019510059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510059A5 JP2019510059A5 JP2018551287A JP2018551287A JP2019510059A5 JP 2019510059 A5 JP2019510059 A5 JP 2019510059A5 JP 2018551287 A JP2018551287 A JP 2018551287A JP 2018551287 A JP2018551287 A JP 2018551287A JP 2019510059 A5 JP2019510059 A5 JP 2019510059A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- solid dispersion
- dispersion according
- pharmaceutically acceptable
- high molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007962 solid dispersion Substances 0.000 claims 16
- 239000000463 material Substances 0.000 claims 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000011975 tartaric acid Substances 0.000 claims 3
- 235000002906 tartaric acid Nutrition 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229920001531 copovidone Polymers 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 150000007522 mineralic acids Chemical class 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920003081 Povidone K 30 Polymers 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 229940045996 isethionic acid Drugs 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610187046.8 | 2016-03-29 | ||
| CN201610187046.8A CN105816437B (zh) | 2016-03-29 | 2016-03-29 | 一种帕布昔利布的药物制剂及其制备方法 |
| PCT/CN2016/086546 WO2017166451A1 (zh) | 2016-03-29 | 2016-06-21 | 一种帕布昔利布的药物制剂及其制备方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191821A Division JP2021046410A (ja) | 2016-03-29 | 2020-11-18 | パルボシクリブの医薬製剤およびその調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510059A JP2019510059A (ja) | 2019-04-11 |
| JP2019510059A5 true JP2019510059A5 (enExample) | 2019-07-25 |
| JP6799612B2 JP6799612B2 (ja) | 2020-12-16 |
Family
ID=56525006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551287A Active JP6799612B2 (ja) | 2016-03-29 | 2016-06-21 | パルボシクリブの医薬製剤およびその調製方法 |
| JP2020191821A Pending JP2021046410A (ja) | 2016-03-29 | 2020-11-18 | パルボシクリブの医薬製剤およびその調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191821A Pending JP2021046410A (ja) | 2016-03-29 | 2020-11-18 | パルボシクリブの医薬製剤およびその調製方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US10449195B2 (enExample) |
| EP (1) | EP3437637B1 (enExample) |
| JP (2) | JP6799612B2 (enExample) |
| KR (1) | KR102386665B1 (enExample) |
| CN (2) | CN109078006B (enExample) |
| AU (1) | AU2016400468B2 (enExample) |
| CA (1) | CA3019257C (enExample) |
| EA (1) | EA201892173A1 (enExample) |
| ES (1) | ES2968132T3 (enExample) |
| GB (2) | GB2583425B (enExample) |
| IL (1) | IL261989B2 (enExample) |
| WO (1) | WO2017166451A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017025398A2 (pt) | 2015-06-04 | 2018-08-07 | Pfizer Inc. | formas de dosagem sólidas de palbociclib |
| CN109078006B (zh) | 2016-03-29 | 2021-04-20 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| CN108017629A (zh) * | 2016-11-04 | 2018-05-11 | 上海奥博生物医药技术有限公司 | 一种帕博西尼无定形态 |
| CN108210454A (zh) * | 2016-12-14 | 2018-06-29 | 深圳市华力康生物医药有限公司 | 一种帕布昔利布的口服乳剂及其制备方法 |
| WO2018191950A1 (en) * | 2017-04-21 | 2018-10-25 | Alnova Pharmaceuticals, Ltd. | Palbociclib compositions and methods thereof |
| WO2019056163A1 (zh) * | 2017-09-19 | 2019-03-28 | 浙江华海药业股份有限公司 | N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法 |
| CN108014343A (zh) * | 2017-12-21 | 2018-05-11 | 孟斯琴 | 一种治疗乳腺癌的药物组合物及其制备方法 |
| CN108066312B (zh) * | 2017-12-29 | 2020-03-20 | 山东裕欣药业有限公司 | 一种帕博西尼药物组合物及其制备方法 |
| CN108066303A (zh) * | 2017-12-31 | 2018-05-25 | 湖南博隽生物医药有限公司 | 一种抗癌药物组合物及其制备方法 |
| HUE064843T2 (hu) | 2018-05-14 | 2024-04-28 | Pfizer | Orális oldat kiszerelés |
| CN108653222A (zh) * | 2018-07-03 | 2018-10-16 | 威海贯标信息科技有限公司 | 一种帕博西尼片剂组合物 |
| CN109288806A (zh) * | 2018-08-22 | 2019-02-01 | 深圳市华力康生物医药有限公司 | 一种帕布昔利布的泡腾片及其应用 |
| CN115989022A (zh) * | 2020-07-02 | 2023-04-18 | 阿瑟姆治疗株式会社 | 口服用药物组合物及其制备方法 |
| WO2022063119A1 (zh) * | 2020-09-24 | 2022-03-31 | 南京济群医药科技股份有限公司 | 一种羟乙磺酸哌柏西利的组合物及药物 |
| CN114306245A (zh) * | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| CN117815184A (zh) * | 2020-12-28 | 2024-04-05 | 上海云晟研新生物科技有限公司 | 帕博西尼固体分散体、其制备方法及应用 |
| CN112870166B (zh) * | 2021-01-20 | 2022-04-08 | 中山大学 | 一种核丛青霉素固体分散体、制备方法及应用 |
| CN114010604B (zh) * | 2021-11-26 | 2022-12-20 | 河南省人民医院 | 一种帕博西尼固体制剂及其制备方法 |
| AU2023239642A1 (en) | 2022-03-25 | 2024-11-07 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions of protac compounds and uses thereof |
| KR20240170460A (ko) * | 2023-05-25 | 2024-12-03 | 주식회사 삼양홀딩스 | 팔보시클립의 경구용 조성물 |
| KR102908668B1 (ko) * | 2023-10-11 | 2026-01-06 | 경희대학교 산학협력단 | 화합물과 설폰산 또는 카르복시산의 결정체, 및 이를 포함하는 유방암 치료를 위한 약학적 조성물 |
| KR20250062261A (ko) | 2023-10-30 | 2025-05-08 | 신풍제약주식회사 | 향상된 용해도 및 안정성을 가지는 팔보시클립의 제약학적 조성물 및 이의 제조방법 |
| WO2025156193A1 (en) * | 2024-01-25 | 2025-07-31 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Palbociclib dosage form |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US745168A (en) | 1903-07-16 | 1903-11-24 | Arthur C Eastwood | System for control of electric motors. |
| US1025860A (en) | 1911-02-25 | 1912-05-07 | Santi Caruso | Coin-operated hat, coat, and umbrella rack. |
| US1016075A (en) | 1911-10-18 | 1912-01-30 | George Kowalsky | Feed-bag. |
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| EP0198395A3 (en) * | 1985-04-09 | 1989-04-12 | Mitsubishi Kasei Corporation | Separating agent for mixed solution |
| US4847092A (en) * | 1985-11-12 | 1989-07-11 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
| ATE238266T1 (de) | 1998-06-03 | 2003-05-15 | Gergely Dr & Co | Mit alkali- bzw. erdalkali-ionen dotierte zitronensäure |
| JP2000309588A (ja) * | 1999-04-28 | 2000-11-07 | Taisho Pharmaceut Co Ltd | 固体分散体 |
| EA003052B1 (ru) | 1999-07-27 | 2002-12-26 | Балканфарма Холдинг АД | Антиаритмическое лекарственное средство |
| CZ20022521A3 (cs) | 2000-01-27 | 2003-02-12 | Warner-Lambert Company | Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění |
| EE200200506A (et) | 2000-03-06 | 2004-02-16 | Warner-Lambert Company | 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid |
| JP2004519422A (ja) | 2000-08-04 | 2004-07-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン |
| EP1929998A3 (en) * | 2001-09-21 | 2008-11-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
| ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| SI1870100T1 (sl) | 2002-03-07 | 2012-05-31 | Boehringer Ingelheim Int | Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10209985A1 (de) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze |
| US7884127B2 (en) * | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
| CN1835951B (zh) | 2003-07-11 | 2010-06-02 | 沃尼尔·朗伯有限责任公司 | 选择性cdk4抑制剂的羟乙基磺酸盐 |
| GB0317663D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| WO2005094830A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| DE102004062864A1 (de) | 2004-12-21 | 2006-06-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Folienbehälter |
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
| WO2006112649A1 (en) | 2005-04-20 | 2006-10-26 | Ctc Bio, Inc. | Pharmaceutical composition containing sibutramine free base and manufacturing method thereof |
| EP1919460A2 (en) | 2005-08-22 | 2008-05-14 | Novartis AG | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| KR20140088230A (ko) * | 2006-01-27 | 2014-07-09 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 |
| WO2009014642A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
| WO2009042114A2 (en) | 2007-09-21 | 2009-04-02 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| CN102231984A (zh) | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护 |
| WO2010055119A2 (en) | 2008-11-17 | 2010-05-20 | Novartis Ag | Pharmaceutical composition comprising pimobendan |
| DE102009028354B4 (de) | 2009-08-07 | 2013-05-29 | Mtu Friedrichshafen Gmbh | Gasführungssystem für eine Peripherie einer Brennkraftmaschine zur Führung von Gas der Brennkraftmaschine, Brennkraftsystem und Verfahren zum Betrieb der Brennkraftmaschine |
| AU2010321773A1 (en) | 2009-11-20 | 2012-06-14 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| CN102106807B (zh) * | 2009-12-29 | 2013-03-27 | 上海中西制药有限公司 | 一种固体制剂的制备方法及所得固体制剂 |
| CN102106806B (zh) * | 2009-12-29 | 2013-04-17 | 上海中西制药有限公司 | 一种固体制剂的制备方法及所得固体制剂 |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| KR20130109092A (ko) * | 2010-06-09 | 2013-10-07 | 아보트 러보러터리즈 | 키나제 억제제를 함유하는 고체 분산물 |
| AR086913A1 (es) | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| WO2013078264A1 (en) * | 2011-11-23 | 2013-05-30 | Novartis Ag | Pharmaceutical formulations |
| CN104487594A (zh) | 2012-07-09 | 2015-04-01 | 诺华股份有限公司 | 与cdk抑制剂相关的生物标志物 |
| WO2014121235A2 (en) * | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| AU2014220354B2 (en) | 2013-02-21 | 2018-02-01 | Pfizer Inc. | Solid forms of a selective CDK4/6 inhibitor |
| EP2986740B1 (en) | 2013-04-16 | 2020-01-15 | Memorial Sloan-Kettering Cancer Center | Companion diagnostic for cdk4 inhibitors |
| CN111012756B (zh) | 2013-06-21 | 2023-06-13 | 四川海思科制药有限公司 | 一种达比加群酯药物组合物及其制备方法 |
| SI3033086T1 (sl) | 2013-08-14 | 2022-01-31 | Novartis Ag | Kombinirana terapija za zdravljenje raka |
| CN105899232A (zh) * | 2013-11-13 | 2016-08-24 | 诺华股份有限公司 | 用于增强免疫应答的mTOR抑制剂 |
| US20170067116A1 (en) | 2014-03-04 | 2017-03-09 | The Regents Of The University Of California | Biomarkers of Response to Cyclin D-CDK4/6 Targeted Therapies in Cancer |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| HRP20191716T1 (hr) | 2014-05-01 | 2019-12-13 | Hermes Arzneimittel Gmbh | Čvrste oralne formulacije koje sadrže čvrste disperzije talina organskih kiselina u ksilitolu |
| CA2954189A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| CN105616418A (zh) | 2014-11-07 | 2016-06-01 | 江苏豪森药业集团有限公司 | 含有细胞周期蛋白抑制剂的药物制剂及其制备方法 |
| CN105616419A (zh) * | 2014-11-07 | 2016-06-01 | 江苏豪森药业集团有限公司 | 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法 |
| CN104434809B (zh) * | 2014-12-10 | 2018-10-16 | 北京科莱博医药开发有限责任公司 | 一种奥拉帕尼固体分散体制剂及其制备方法 |
| RS59782B1 (sr) | 2015-02-03 | 2020-02-28 | Jiangsu Hengrui Medicine Co | Hidroksietil sulfonat od ciklina zavisnog inhibitora kinaze proteina, njegov kristalni oblik, i postupak za njegovo dobijanje |
| CZ201589A3 (cs) | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
| WO2016156070A1 (en) * | 2015-04-02 | 2016-10-06 | Sandoz Ag | Modified particles of palbociclib |
| CN104887641B (zh) * | 2015-04-08 | 2017-12-01 | 上海鲁源医药科技有限公司 | 帕布昔利布胃漂浮片及其制备方法 |
| BR112017025398A2 (pt) | 2015-06-04 | 2018-08-07 | Pfizer Inc. | formas de dosagem sólidas de palbociclib |
| ES2741958T3 (es) | 2015-08-05 | 2020-02-12 | Ratiopharm Gmbh | Nueva forma cristalina y aductos de ácido acético de palbociclib |
| CN105085517B (zh) | 2015-08-06 | 2016-11-23 | 天津华洛康生物科技有限公司 | 一种结晶型帕博西尼游离碱水合物及其制备方法 |
| WO2017036390A1 (zh) * | 2015-09-01 | 2017-03-09 | 上海方楠生物科技有限公司 | 帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
| CN107510847A (zh) | 2016-06-16 | 2017-12-26 | 常州方楠医药技术有限公司 | 一种含有无定型帕博西林固体分散体的药用组合物及其制备方法 |
| CN106474129A (zh) * | 2015-09-01 | 2017-03-08 | 上海方楠生物科技有限公司 | 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
| CN105213322A (zh) | 2015-10-30 | 2016-01-06 | 南京正大天晴制药有限公司 | 一种干法制粒工艺制备的药物组合物 |
| CN106831710A (zh) | 2015-12-07 | 2017-06-13 | 常州爱诺新睿医药技术有限公司 | 一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法 |
| WO2017115315A1 (en) * | 2015-12-30 | 2017-07-06 | Dr. Reddy's Laboratories Limited | Solid forms of palbociclib |
| CN106967061A (zh) | 2016-01-13 | 2017-07-21 | 常州方楠医药技术有限公司 | 帕博西林的盐、晶型及其制备方法 |
| WO2017130219A1 (en) | 2016-01-25 | 2017-08-03 | Mylan Laboratories Limited | Amorphous solid dispersion of palbociclib |
| AU2017235450A1 (en) | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| WO2017172734A1 (en) | 2016-03-29 | 2017-10-05 | Mayo Foundation For Medical Education And Research | Treating cancer metastasis |
| CN109078006B (zh) | 2016-03-29 | 2021-04-20 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| CN105748435B (zh) | 2016-04-21 | 2019-03-29 | 石家庄海瑞药物科技有限公司 | 一种帕布昔利布药物组合物及其制备方法 |
| EP3458604B1 (en) | 2016-05-18 | 2021-04-14 | Université Libre de Bruxelles | Method for determining sensitivity to a cdk4/6 inhibitor |
| EP3255048A1 (en) | 2016-06-07 | 2017-12-13 | K.H.S. Pharma Holding GmbH | Non-crystalline form of palbociclib |
| NZ752443A (en) | 2016-10-11 | 2022-11-25 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
| CN108017629A (zh) | 2016-11-04 | 2018-05-11 | 上海奥博生物医药技术有限公司 | 一种帕博西尼无定形态 |
| CN106667952A (zh) | 2016-12-12 | 2017-05-17 | 河南润弘制药股份有限公司 | 一种帕布昔利布药物组合物及其制备方法 |
| WO2018191950A1 (en) | 2017-04-21 | 2018-10-25 | Alnova Pharmaceuticals, Ltd. | Palbociclib compositions and methods thereof |
| CN108864078B (zh) | 2017-05-10 | 2021-10-15 | 江苏豪森药业集团有限公司 | 帕博西尼晶型b的制备方法 |
| WO2019056163A1 (zh) | 2017-09-19 | 2019-03-28 | 浙江华海药业股份有限公司 | N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法 |
| CN108014343A (zh) | 2017-12-21 | 2018-05-11 | 孟斯琴 | 一种治疗乳腺癌的药物组合物及其制备方法 |
| CN108066312B (zh) | 2017-12-29 | 2020-03-20 | 山东裕欣药业有限公司 | 一种帕博西尼药物组合物及其制备方法 |
| CN108066303A (zh) | 2017-12-31 | 2018-05-25 | 湖南博隽生物医药有限公司 | 一种抗癌药物组合物及其制备方法 |
| WO2019178239A1 (en) | 2018-03-13 | 2019-09-19 | Board Of Regents, The University Of Texas System | Methods for treatment of cancers with egfr activating mutations |
| CN108272754A (zh) | 2018-04-11 | 2018-07-13 | 吴小戈 | 一种抗癌药物固体分散体组合物及其制备方法 |
| HUE064843T2 (hu) | 2018-05-14 | 2024-04-28 | Pfizer | Orális oldat kiszerelés |
| CN108653222A (zh) | 2018-07-03 | 2018-10-16 | 威海贯标信息科技有限公司 | 一种帕博西尼片剂组合物 |
-
2016
- 2016-03-29 CN CN201810902418.XA patent/CN109078006B/zh active Active
- 2016-03-29 CN CN201610187046.8A patent/CN105816437B/zh active Active
- 2016-06-21 KR KR1020187031357A patent/KR102386665B1/ko active Active
- 2016-06-21 IL IL261989A patent/IL261989B2/en unknown
- 2016-06-21 JP JP2018551287A patent/JP6799612B2/ja active Active
- 2016-06-21 CA CA3019257A patent/CA3019257C/en active Active
- 2016-06-21 GB GB2010241.4A patent/GB2583425B/en active Active
- 2016-06-21 ES ES16896224T patent/ES2968132T3/es active Active
- 2016-06-21 AU AU2016400468A patent/AU2016400468B2/en active Active
- 2016-06-21 WO PCT/CN2016/086546 patent/WO2017166451A1/zh not_active Ceased
- 2016-06-21 EA EA201892173A patent/EA201892173A1/ru unknown
- 2016-06-21 EP EP16896224.9A patent/EP3437637B1/en active Active
- 2016-06-21 GB GB1817116.5A patent/GB2564793B/en active Active
-
2017
- 2017-06-05 US US15/613,853 patent/US10449195B2/en active Active
-
2019
- 2019-08-28 US US16/554,112 patent/US10813937B2/en active Active
- 2019-08-28 US US16/554,103 patent/US10894049B2/en active Active
-
2020
- 2020-09-17 US US17/024,389 patent/US11464779B2/en active Active
- 2020-11-18 JP JP2020191821A patent/JP2021046410A/ja active Pending
-
2022
- 2022-09-28 US US17/954,421 patent/US20230226063A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2950995T3 (es) | Un comprimido que comprende un derivado de metoxiurea y partículas de manitol | |
| JP2009530415A5 (enExample) | ||
| JP2023543814A5 (enExample) | ||
| WO2016155655A1 (zh) | Parp抑制剂固体药物剂型及其应用 | |
| RU2008148547A (ru) | Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением | |
| CN101516344A (zh) | 包含尼罗替尼或其盐的药物组合物 | |
| CN107320460B (zh) | 一种尼罗替尼口服纳米制剂及其制备方法 | |
| WO2017140254A1 (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| ES3055123T3 (en) | Pharmaceutical composition comprising enzalutamide | |
| JP2013103899A (ja) | 難溶性薬物の新規な固体分散体 | |
| JP2016539953A (ja) | 経口投与用製剤の製造方法 | |
| JP2017505800A5 (enExample) | ||
| ES3018260T3 (en) | Method for producing an apixaban granulate | |
| TW201311246A (zh) | 使用有機酸助溶之４－甲基－３－［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺之修飾釋放調配物 | |
| RU2016130161A (ru) | Покрытия для медицинских изделий | |
| Jiao et al. | Recent progresses in bioadhesive microspheres via transmucosal administration | |
| JP2021059551A (ja) | フェニルアミノピリミジン誘導体を含む医薬組成物 | |
| JP2019501191A5 (enExample) | ||
| JP6293315B2 (ja) | アリサルタン・イソプロキシル固体分散体及び該固体分散体を含有する医薬組成物 | |
| TWI574690B (zh) | 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物 | |
| ES2424865T3 (es) | Formulación farmacéutica oral de liberación rápida para esomeprazol | |
| HRP20211985T1 (hr) | Farmaceutska vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu | |
| CN104800184B (zh) | 琥珀酸呋罗曲坦缓释剂片 | |
| ES2607440T3 (es) | Formulaciones de aripiprazol | |
| CN104271134B (zh) | 含有5-羟基-1h-咪唑-4-甲酰胺的片剂 |